Summary
TASER International, Inc. (now Axon Enterprise, Inc.) announced the re-appointment of Dr. Matthew R. McBrady to its Board of Directors, effective October 5, 2016. Dr. McBrady, who previously served on the board from 2001 to 2014, brings a wealth of experience in economics, academia, private equity, and investment management, most recently serving as Managing Director and Chief Investment Officer at BlackRock's Multi-Strategy Hedge Fund Platform. His return is expected to strengthen the board's expertise, particularly in financial and strategic matters, as he is anticipated to join the Audit and Nominating and Corporate Governance Committees. The compensation for Dr. McBrady aligns with the existing director compensation program, including an initial restricted stock award valued at $100,000 vesting over four years, an annual restricted stock-incentive award of $80,000 vesting over three years, and an annual cash compensation of $35,000. This re-appointment signals a strategic move by the company to leverage experienced financial leadership as it continues to grow and evolve.
Key Highlights
- 1Dr. Matthew R. McBrady re-appointed to the Board of Directors.
- 2Dr. McBrady previously served on the board from January 2001 to June 2014.
- 3Expected to be appointed to the Audit and Nominating and Corporate Governance Committees.
- 4Compensation includes a $100,000 initial restricted stock award (4-year vesting), an $80,000 annual restricted stock award (3-year vesting), and $35,000 annual cash compensation.
- 5Dr. McBrady possesses extensive experience in economics, academia (Wharton, Darden), private equity (Bain Capital), and investment management (Silver Creek Capital, BlackRock).
- 6His most recent role was Managing Director and Chief Investment Officer at BlackRock's Multi-Strategy Hedge Fund Platform.
- 7The filing also lists a press release dated October 12, 2016, as an exhibit.